In Vivo Photodynamic Characteristics of the Near-Infrared Photosensitizer 5,10,15,20-Tetrakis(M-Hydroxyphenyl) Bacteriochlorin¶

Abstract This paper describes the photodynamic characteristics of the new near-infrared photosensitizer 5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin (mTHPBC or SQN400) in normal rat and mouse tissues. A rat liver model of photodynamic tissue necrosis was used to determine the in vivo action spectrum and the dose–response relationships of tissue destruction with drug and light doses. The effect of varying the light irradiance and the time interval between drug administration and light irradiation on the biological response was also measured in the rat liver model. Photobleaching of mTHPBC was measured and compared with that of its chlorin analog (mTHPC) in normal mouse skin and an implanted mouse colorectal tumor. The optimum wavelength for biological activation of mTHPBC in rat liver was 739 nm. mTHPBC was found to have a marked drug-dose threshold of around 0.6 mg kg−1 when liver tissue was irradiated 48 h after drug administration. Below this administered drug dose, irradiation, even at very high light doses, did not cause liver necrosis. At administered doses above the photodynamic threshold the effect of mTHPBC–PDT was directly proportional to the product of the drug and light doses. No difference in the extent of liver necrosis produced by mTHPBC was found on varying the light irradiance from 10 to 100 mW cm−2. The extent of liver necrosis was greatest when tissue was irradiated shortly after mTHPBC administration and necrosis was absent when irradiation was performed 72 h or later after drug administration, suggesting that the drug was rapidly cleared from the liver. In vivo photobleaching experiments in mice showed that the rate of bleaching of mTHPBC was approximately 20 times greater than that of mTHPC. It is argued that this greater rate of bleaching accounts for the higher photodynamic threshold and this could be exploited to enhance selective destruction of tissues which accumulate the photosensitizer.

[1]  A. E. Saarnak,et al.  Biodistribution and Bioactivity of Tetra-pegylated Meta-tetra(hydroxyphenyl)chlorin Compared to Native Meta-tetra(hydroxyphenyl)chlorin in a Rat Liver Tumor Model , 2000 .

[2]  R. Bonnett,et al.  Photobleaching of 5,10,15,20-tetrakis(m-hydroxyphenyl)porphyrin (m-THPP) and the corresponding chlorin (m-THPC) and bacteriochlorin(m-THPBC). A comparative study , 1999 .

[3]  J. J. Schuitmaker,et al.  Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model , 1999, British Journal of Cancer.

[4]  P. Siersema,et al.  Timing of illumination is essential for effective and safe photodynamic therapy: a study in the normal rat oesophagus , 1999, British Journal of Cancer.

[5]  J. J. Schuitmaker,et al.  Interstitial photodynamic therapy with the second-generation photosensitizer bacteriochlorin a in a rat model for liver metastases. , 1998, British Journal of Cancer.

[6]  F. Guillemin,et al.  Parameters Affecting Photodynamic Activity of Foscan® or Meta-tetra(hydroxyphenyl)chlorin (mTHPC) In Vitro and In Vivo , 1998, Lasers in Medical Science.

[7]  B. Henderson,et al.  The Effect of Fluence Rate on Tumor and Normal Tissue Responses to Photodynamic Therapy , 1998, Photochemistry and photobiology.

[8]  N. Williams,et al.  Intracellular uptake, absorption spectrum and stability of the bacteriochlorin photosensitizer 5,10,15,20-tetrakis(m-hydroxyphenyl) bacteriochlorin (mTHPBC). Comparison with 5,10,15,20-tetrakis(m-hydroxyphenyl) chlorin (mTHPC) , 1997 .

[9]  H. Bergh,et al.  In Vivo Fluence Rate Effect in Photodynamic Therapy of Early Cancers with Tetra(m‐hydroxyphenyl)chlorin , 1996, Photochemistry and photobiology.

[10]  H. Oppelaar,et al.  Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. , 1996, Radiation research.

[11]  H. Messmann,et al.  Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. , 1995, British Journal of Cancer.

[12]  F. Stewart,et al.  Functional and histological bladder damage in mice after photodynamic therapy: the influence of sensitiser dose and time of administration. , 1993, British Journal of Cancer.

[13]  R. van Hillegersberg,et al.  Interstitial photodynamic therapy in a rat liver metastasis model. , 1992, British Journal of Cancer.

[14]  M Chopp,et al.  The effect of light fluence rate in photodynamic therapy of normal rat brain. , 1992, Radiation research.

[15]  D. Thompson,et al.  Triggered release of hydrophilic agents from plasmalogen liposomes using visible light or acid. , 1992, Biochimica et biophysica acta.

[16]  T. Foster,et al.  Oxygen consumption and diffusion effects in photodynamic therapy. , 1991, Radiation research.

[17]  B. Tromberg,et al.  In vivo TUMOR OXYGEN TENSION MEASUREMENTS FOR THE EVALUATION OF THE EFFICIENCY OF PHOTODYNAMIC THERAPY , 1990, Photochemistry and photobiology.

[18]  T. Mukherjee,et al.  Triplet excited states and semiquinone radicals of 1,4-disubstituted anthraquinones , 1990 .

[19]  M C Berenbaum,et al.  Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. , 1989, The Biochemical journal.

[20]  W. Potter,et al.  DRUG AND LIGHT DOSE DEPENDENCE OF PHOTODYNAMIC THERAPY: A STUDY OF TUMOR CELL CLONOGENICITY AND HISTOLOGIC CHANGES , 1987, Photochemistry and photobiology.

[21]  R. Bonnett,et al.  meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. , 1986, British Journal of Cancer.

[22]  P. D. Smith,et al.  Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver. , 1986, British Journal of Cancer.

[23]  S. Gibson,et al.  INTERDEPENDENCE OF FLUENCE, DRUG DOSE and OXYGEN ON HEMATOPORPHYRIN DERIVATIVE INDUCED PHOTOSENSITIZATION OF TUMOR MITOCHONDRIA , 1985, Photochemistry and photobiology.

[24]  I. Forbes,et al.  Photocytotoxicity in vivo of haematoporphyrin derivative components. , 1985, Cancer letters.

[25]  G. H. Gijsbers,et al.  Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. , 1985, British Journal of Cancer.

[26]  C. Gomer,et al.  In vitro and in vivo light dose rate effects related to hematoporphyrin derivative photodynamic therapy. , 1985, Cancer research.

[27]  D. Lankin,et al.  Oxo pyrazoline spiro oxiranes a new class of reactive hetero cycles , 1983 .

[28]  T. G. Truscott,et al.  Photophysical properties of 5,10,15,20-tetrakis(m-hydroxyphenyl)porphyrin (m-THPP), 5,10,15,20-tetrakis(m-hydroxyphenyl)chlorin (m-THPC) and 5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin (m-THPBC): a comparative study , 1999 .

[29]  W. Star.  In vivo action spectra, absorption and fluorescence excitation spectra of photosensitizers for photodynamic therapy. , 1995, Journal of photochemistry and photobiology. B, Biology.

[30]  B. Wilson,et al.  Light propagation in animal tissues in the wavelength range 375-825 nanometers. , 1984, Progress in clinical and biological research.